Skip to main content
ALGORAE PHARMACEUTICALS LIMITED logo

ALGORAE PHARMACEUTICALS LIMITED — Investor Relations & Filings

Ticker · 1AI ISIN · AU0000296022 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,159 across all filing types
Latest filing 2009-06-09 Director's Dealing
Country AU Australia
Listing ASX 1AI

About ALGORAE PHARMACEUTICALS LIMITED

https://algoraepharma.com/

Algorae Pharmaceuticals Limited is a biopharmaceutical company focused on the discovery and development of novel therapeutic solutions for complex medical conditions. The company leverages its proprietary artificial intelligence platform, AlgoraeOS, to streamline the drug discovery process and identify synergistic drug combinations. Its research pipeline primarily targets neurodegenerative diseases and other areas of high unmet clinical need. Key development programs include AI-116, a combination therapy aimed at treating dementia and Alzheimer's disease. By integrating advanced computational modeling with traditional pharmacological research, the company seeks to accelerate the transition of candidates from preclinical stages to clinical trials, optimizing therapeutic efficacy and safety profiles.

Recent filings

Filing Released Lang Actions
Change of Director`s Interest Notice 3 pages ?Kb
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a director, including dates, number of shares/options acquired or disposed, and nature of the changes. This is a formal notification of personal share transactions by a company director. There is no financial performance data, earnings information, or management discussion. The document fits the definition of Director's Dealing, which reports personal share transactions by company directors and executives (insider trades). The document length and content confirm it is not a brief announcement or a report publication notice but the actual notice of director's interest change.
2009-06-09 English
Change of Director`s Interest Notice 2 pages ?Kb
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a director, including shares and options held before and after the change, dates of changes, and nature of changes such as lapsed options and off-market trades. This type of document is a formal notification of personal share transactions by a company director. It does not contain financial performance data, management discussion, or other report content. Therefore, it fits the definition of a Director's Dealing report.
2009-06-09 English
Trading Halt 2 pages ?Kb
Regulatory Filings
2009-05-21 English
Living Cell Technologies - Capital Raising Cancelled 2 pages ?Kb
Capital/Financing Update Classification · 95% confidence The document is a company announcement from Living Cell Technologies Limited dated 22 May 2009. It announces the cancellation of a planned capital raising of NZD5 million. The content focuses on the cancellation of a financing activity and does not contain financial statements, detailed financial analysis, or regulatory filings. It is not a full financial report, earnings release, or management discussion. The document is short (4733 characters) and serves as an update on capital raising plans. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2009-05-21 English
LCT Clinical Trial 2 Patients achieve insulin independence 3 pages ?Kb
Regulatory Filings Classification · 85% confidence The document is a company announcement from Living Cell Technologies Limited reporting clinical trial results for their DIABECELL product. It provides detailed clinical trial data, patient follow-up information, and efficacy results. The document is not a full annual or interim financial report, nor is it a regulatory filing or certification. It is a progress update on a clinical trial, which is a form of operational update rather than a financial or governance report. The document length is over 10,000 characters, indicating it is a substantive announcement rather than a brief notice. The content focuses on clinical trial progress and results, which aligns with a general company announcement or regulatory filing category. Since it does not fit into any specific financial or governance filing categories, the best fit is Regulatory Filings (RNS), which is the fallback for miscellaneous company announcements and updates that do not fit other categories.
2009-05-04 English
LCT Director Steps Down 1 page ?Kb
Board/Management Information Classification · 100% confidence The document is a company announcement from Living Cell Technologies Limited dated 1 May 2009, stating that a director, Robert Caspari, has stepped down. It includes contact information and a company description but contains no financial data, no report or presentation, and no mention of voting results or other regulatory filings. The content is focused solely on a change in the company's board of directors. The document length is 4474 characters, which is relatively short and consistent with a management or board change announcement. Therefore, the document fits the category of Board/Management Information (MANG).
2009-04-30 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.